RxDoctor Payments DataLook up a doctor →

John Tauro, DO

Neuromuscular Medicine · Norwich, CTNPI 1003915778

Payments from drug & device makers

$53,731in general payments, 2019–2025

Across 951 payments — averaging $56.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$41K
  • Pfizer$2K
  • UCB, Inc.$846
  • Teva Pharmaceuticals USA, Inc.$647
  • Lundbeck LLC$621
  • Amgen$585
  • plus $8K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)331$41,305
Pfizer73$1,627
UCB, Inc.33$846
Teva Pharmaceuticals USA, Inc.38$647
Lundbeck LLC26$621
Amgen(2 entities)29$585
Biogen27$565
AstraZeneca(2 entities)25$529
Sanofi29$489
Biohaven Pharmaceutical Holding Company Ltd.22$475
CSL Behring22$436
Takeda Pharmaceuticals U.S.A., Inc.17$389
SK Life Science, Inc.14$368
Sunovion Pharmaceuticals Inc.29$359
EMD Serono, Inc.13$331
Eisai Inc.15$327
Novartis23$297
Genentech USA, Inc.13$283
Octapharma USA, Inc.12$279
Biohaven Pharmaceuticals, Inc.15$269
Avanir Pharmaceuticals, Inc.14$255
Johnson & Johnson(2 entities)9$189
Lilly USA, LLC10$176
Scilex Pharmaceuticals Inc.8$175
Argenx US, Inc.7$167
Mallinckrodt Hospital Products Inc.7$135
Amneal Pharmaceuticals LLC7$116
Tanabe Pharma America, Inc.6$112
Grifols USA, LLC6$101
Impel Pharmaceuticals Inc.6$84
Axsome Therapeutics, Inc.4$78
Cycle Pharmaceuticals Inc4$78
Bristol Myers Squibb3$73
Alnylam Pharmaceuticals Inc.4$69
Neurocrine Biosciences, Inc.3$63
Currax Pharmaceuticals LLC4$59
Otsuka America Pharmaceutical, Inc.3$58
TG Therapeutics, Inc.2$53
Supernus Pharmaceuticals, Inc.4$52
Mallinckrodt Enterprises LLC2$52
Ipsen Biopharmaceuticals, Inc3$52
Averitas Pharma Inc.2$45
Kyowa Kirin, Inc.2$42
Upsher-smith Laboratories LLC3$42
Life Molecular Imaging Ltd3$35
Almatica Pharma LLC2$34
Sumitomo Pharma America, Inc.3$32
GE HealthCare1$30
Assertio Therapeutics, Inc.2$29
Vanda Pharmaceuticals Inc.1$28
ANI Pharmaceuticals, Inc.1$23
Collegium Pharmaceutical, Inc.1$22
Catalyst Pharmaceuticals, Inc.1$22
Banner Life Sciences, LLC1$21
Sanofi-aventis U.S. LLC1$19
Tonix Medicines, Inc.1$19
Amylyx Pharmaceuticals, Inc.1$18
Kedrion Biopharma, Inc.1$17
Neurelis, Inc.1$15
Merz Pharmaceuticals, LLC1$14

How this compares

Too few neuromuscular medicine providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$168,676
Medicare patients
241
Services billed
32,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neuromuscular medicine in Norwich

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →